Latest Remediation News

ASX Compliance has flagged Rent.com.au Limited for a late filing of a director’s interest change, raising questions about the company’s disclosure controls and compliance with listing rules.

Capricorn Metals Ltd’s CMMO securities have been reinstated to trading on the ASX after meeting compliance requirements, signaling renewed market activity. Investors will be watching closely to gauge the impact on liquidity and price movement.

Bendigo and Adelaide Bank has revealed systemic deficiencies in its anti-money laundering and counter-terrorism financing controls following a Deloitte investigation, committing to comprehensive remediation efforts.

Alfabs Australia Limited reported robust financial gains in FY2025, including a maiden dividend and major contract completion, while signaling cautious optimism for 2026 amid softer markets and uncertain project pipelines.

Dusk Group Limited has addressed an ASX compliance query regarding the delayed disclosure of a director’s interest change, attributing the lapse to an administrative oversight while reaffirming its commitment to regulatory compliance.

The Star Entertainment Group has secured crucial regulatory approvals to convert a $300 million strategic investment by Bally’s Corporation and Investment Holdings into equity, setting the stage for board changes and a path toward financial recovery.

DroneShield Limited has clarified the recent exercise and sale of shares by its directors following performance option vesting, alongside addressing an erroneous contract announcement that was later withdrawn. The company also outlined steps to enhance compliance with ASX continuous disclosure and trading policies.

Stealth Group Holdings has explained the late filing of a director’s interest notice as an administrative oversight, assuring no market harm occurred. The company has since strengthened its compliance controls to prevent future lapses.

Environmental Clean Technologies is set to convert a $1.13 million convertible note into equity, significantly reducing debt and freeing resources to advance its PFAS remediation technology.

Aspermont Limited’s shares have been suspended from trading due to a critical shortfall in board directors, raising questions about its governance and future compliance.

Antaria has disclosed several FDA-identified GMP compliance issues but assures no impact on product quality or supply, committing to expert-led remediation and enhanced training.

Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.